Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

Hims & Hers entered an agreement with Eli Lilly regarding GLP-1 medications. Under the deal, Hims said it will not compound GLP-1 medications such as Zepbound in the future. Hims & Hers stock rose following the announcement.

• MarketWatch — Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

Next story